摘要
人表皮生长因子受体2（HER2）在20％～30％的乳腺癌患者中过表达。针对HER2的分子靶向治疗可从分子水平抑制乳腺癌细胞生长。目前乳腺癌的分子靶向治疗药物主要有作用于HER2的单克隆抗体和酪氨酸激酶抑制剂两类。曲妥珠单抗已临床用于治疗HER2阳性的转移性乳腺癌，对HER2阳性的早期乳腺癌也有一定疗效。拉帕替尼对难治性乳腺癌和乳腺癌脑转移的治疗有很大潜力。该类药物在乳腺癌治疗领域中存在着巨大潜力。
Human epidermal growth factor receptor 2 （HER2） is expressed in 20%- 30% of the patients with breast cancer. The HER2-targeted molecule-targeted therapy suppresses the growth of malignant cell in the molecule level. Monoclonal antibodies and tyrosine kinase inhibitors are two main kinds of molecule- targeted drugs. Trastuzumab is applied on HER2-positive metastatic breast cancer clinically, there is also a considerable clinical benefit from the application of trastuzumab in the HER2-positive early-stage breast cancer. Lapatinib shows a considerable potential in the treatment of refractory breast cancer and brain metastases from breast cancer. The HELL2-targeted molecule-targeted drugs show a considerable potential in the drug treatment of breast cancer.
出处
《国际肿瘤学杂志》
CAS
2010年第2期134-137,共4页
Journal of International Oncology
基金
国家自然科学基金资助项目（30870975）
